


Author index of volume 50

- Abdella, N., A.O. Akanji, O.A. Mojiminiyi, A. Al Assoussi, M. Moussa, Relation of serum total sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti Type 2 diabetic patients **50**, 65
- Abdella, N., O.A. Mojiminiyi, A.O. Akanji, Homocysteine and endogenous markers of renal function in type 2 diabetic patients without coronary heart disease **50**, 177
- Abiko, A., see Matsumoto, A. **50**, 195
- Ah Kim, K., see Suk, K. **50**, 17
- Aiso, Y., see Kawasaki, T. **50**, 97
- Akanji, A.O., see Abdella, N. **50**, 65
- Akanji, A.O., see Abdella, N. **50**, 177
- Al Assoussi, A., see Abdella, N. **50**, 65
- Amemiya, S., see Nakamoto, S. **50**, 147
- Andersson, P.-O., see Stenström, U. **50**, 103
- Anwaar, I., A. Gottsäter, K.-F. Eriksson, L. Jacobsson, F. Lindgärde, I. Mattiasson, Increased plasma endothelin-1 and intraplatelet cyclic guanosine monophosphate in men with disturbed glucose metabolism **50**, 127
- Barrow, B.A., see MacNamara, C.M. **50**, 117
- Bayer, A.J., see Sinclair, A.J. **50**, 203
- Buschard, K., see Jørgensen, K.H. **50**, 161
- Çakatay, U., see Telci, A. **50**, 213
- Cha, B.-S., see Nam, J.-H. **50**, 169
- Cheng, P.S., see Wong, G.W.K. **50**, 187
- Clark, A., see MacNamara, C.M. **50**, 117
- Davis, G., see Ezenwaka, C.E. **50**, 137
- Davis, T.M.E., M. Knuiman, P. Kendall, H. Vu, W.A. Davis, Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study **50**, 153
- Davis, W.A., see Davis, T.M.E. **50**, 153
- De Decker, L., see Van Acker, K. **50**, 87
- De Leeuw, I., see Van Acker, K. **50**, 87
- Dys, H., see Van Acker, K. **50**, 87
- Eriksson, K.-F., see Anwaar, I. **50**, 127
- Eto, M., see Matsumoto, A. **50**, 195
- Ezenwaka, C.E., G. Davis, Increased risk of cardiovascular disease in newly diagnosed Type 2 diabetic patients in a primary health care center in Trinidad **50**, 137
- Fjellstrom, C.A., see Sandberg, G.E. **50**, 27
- Fujimori, S., see Kawasaki, T. **50**, 97
- Girling, A.J., see Sinclair, A.J. **50**, 203
- Gottsäter, A., see Anwaar, I. **50**, 127
- Grangé, V., see Halimi, S. **50**, 49
- Halimi, S., M.A. Le Berre, V. Grangé, Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study **50**, 49
- Hansen, A.K., see Jørgensen, K.H. **50**, 161
- Harada, H., see Ito, C. **50**, 225
- Huh, K.-B., see Nam, J.-H. **50**, 169
- Hwang, D.-Y., see Suk, K. **50**, 17
- Inoue, T., see Kawasaki, T. **50**, 97
- Ishida, S., see Ito, C. **50**, 225
- Ito, C., R. Maeda, S. Ishida, H. Sasaki, H. Harada, Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c **50**, 225
- Iwashima, Y., see Matsumoto, A. **50**, 195
- Jacobsson, L., see Anwaar, I. **50**, 127
- Jonsson, P.M., L.Å. Marké, L. Nyström, S. Wall, J. Östman, Excess costs of medical care 1 and 8 years after diagnosis of diabetes: estimates from young and middle-aged incidence cohorts in Sweden **50**, 35
- Jørgensen, K.H., A.K. Hansen, K. Buschard, Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs **50**, 161
- Kashiwabara, A., see Kawasaki, T. **50**, 97

- Kasuga, A., see Nakamoto, S. 50, 147
- Kato, N., K. Mizuno, M. Makino, T. Suzuki, S. Yagihashi, Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats 50, 77
- Kawasaki, T., T. Yamanouchi, A. Kashiwabara, T. Inoue, T. Yoshimura, S. Fujimori, T. Tanabe, Y. Aiso, The influence of traditional Chinese herbal drugs on serum 1,5-anhydroglucitol levels 50, 97
- Keinänen-Kiukaanniemi, S., see Rajala, U. 50, 231
- Kendall, P., see Davis, T.M.E. 50, 153
- Kim, K.-R., see Nam, J.-H. 50, 169
- Kim, S., see Suk, K. 50, 17
- Kim, Y.-H., see Nam, J.-H. 50, 169
- Kim, Y.-H., see Suk, K. 50, 17
- Knuiman, M., see Davis, T.M.E. 50, 153
- Kunitomi, M., K. Takahashi, J. Wada, H. Suzuki, N. Miyatake, S. Ogawa, S. Ohta, H. Sugimoto, K. Shikata, H. Makino, Re-evaluation of exercise prescription for Japanese type 2 diabetic patients by ventilatory threshold 50, 109
- Laakso, M., see Rajala, U. 50, 231
- Le Berre, M.A., see Halimi, S. 50, 49
- Lee, H.-C., see Nam, J.-H. 50, 169
- Lee, M.-S., see Suk, K. 50, 17
- Lee, S.B., see Suk, K. 50, 17
- Leung, T.F., see Wong, G.W.K. 50, 187
- Levy, J.C., see MacNamara, C.M. 50, 117
- Lim, S.-K., see Nam, J.-H. 50, 169
- Lindgärde, F., see Anwaar, I. 50, 127
- MacNamara, C.M., B.A. Barrow, S.E. Manley, J.C. Levy, A. Clark, R.C. Turner, Parallel changes of proinsulin and islet amyloid polypeptide in glucose intolerance 50, 117
- Maeda, R., see Ito, C. 50, 225
- Makino, H., see Kunitomi, M. 50, 109
- Makino, I., see Matsumoto, A. 50, 195
- Makino, M., see Kato, N. 50, 77
- Manley, S.E., see MacNamara, C.M. 50, 117
- Marké, L.Å., see Jonsson, P.M. 50, 35
- Maruyama, T., see Nakamoto, S. 50, 147
- Matricali, G., see Van Acker, K. 50, 87
- Matsumoto, A., Y. Iwashima, A. Abiko, A. Morikawa, M. Sekiguchi, M. Eto, I. Makino, Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy 50, 195
- Mattiasson, I., see Anwaar, I. 50, 127
- Miyatake, N., see Kunitomi, M. 50, 109
- Mizuno, K., see Kato, N. 50, 77
- Mojiminiyi, O.A., see Abdella, N. 50, 65
- Mojiminiyi, O.A., see Abdella, N. 50, 177
- Morikawa, A., see Matsumoto, A. 50, 195
- Moussa, M., see Abdella, N. 50, 65
- Nagata, M., see Sugaya, A. 50, 57
- Nakamoto, S., A. Kasuga, T. Maruyama, Y. Ozawa, S. Amemiya, T. Saruta, Age of onset, not type of onset, affects the positivity and evanescence of IA-2 antibody 50, 147
- Nam, J.-H., H.-C. Lee, Y.-H. Kim, B.-S. Cha, Y.-D. Song, S.-K. Lim, K.-R. Kim, K.-B. Huh, Identification of glucokinase mutation in subjects with post-renal transplantation diabetes mellitus 50, 169
- Namkung, Y., see Suk, K. 50, 17
- Nyström, L., see Jonsson, P.M. 50, 35
- Ogawa, S., see Kunitomi, M. 50, 109
- Ohta, S., see Kunitomi, M. 50, 109
- Oleen-Burkey, M., see Van Acker, K. 50, 87
- Östman, J., see Jonsson, P.M. 50, 35
- Ozawa, Y., see Nakamoto, S. 50, 147
- Qiao, Q., see Rajala, U. 50, 231
- Rajala, U., Q. Qiao, M. Laakso, S. Keinänen-Kiukaanniemi, Antihypertensive drugs as predictors of Type 2 diabetes among subjects with impaired glucose tolerance 50, 231
- Salman, S., see Telci, A. 50, 213
- Sandberg, G.E., H.E. Sundberg, C.A. Fjellstrom, K.F. Wikblad, Type 2 diabetes and oral health: A comparison between diabetic and non-diabetic subjects 50, 27
- Saruta, T., see Nakamoto, S. 50, 147
- Sasaki, H., see Ito, C. 50, 225
- Satman I., see Telci, A. 50, 213
- Sekiguchi, M., see Matsumoto, A. 50, 195
- Seo, Y.-S., see Suk, K. 50, 17
- Shikata, K., see Kunitomi, M. 50, 109
- Shin, H.-S., see Suk, K. 50, 17
- Sinclair, A.J., A.J. Girling, A.J. Bayer, Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services 50, 203
- Sivas, A., see Telci, A. 50, 213
- Sobol, A.B., C. Watala, The role of platelets in diabetes-related vascular complications 50, 1
- Song, Y.-D., see Nam, J.-H. 50, 169
- Stenström, U., P.-O. Andersson, Smoking, blood glucose control, and locus of control beliefs in people with Type 1 diabetes mellitus 50, 103
- Sugaya, A., T. Sugiyama, M. Nagata, N. Toyoda, Comparison of the validity of the criteria for gestational diabetes mellitus by WHO and by the Japan Society of Obstetrics and Gynecology by the outcomes of pregnancy 50, 57
- Sugimoto, H., see Kunitomi, M. 50, 109
- Sugiyama, T., see Sugaya, A. 50, 57
- Suh, Y.-L., see Suk, K. 50, 17
- Suk, K., D.-Y. Hwang, S. Kim, Y.-H. Kim, K. Ah Kim, Y.-S. Seo, Y.-L. Suh, S.B. Lee, Y. Namkung, H.-S. Shin, M.-S. Lee, Identity of mouse IA-2 and PTP35 genes of the tyrosine phosphatase family, and their expression in neuroendocrine tissues 50, 17
- Sundberg, H.E., see Sandberg, G.E. 50, 27
- Suzuki, H., see Kunitomi, M. 50, 109
- Suzuki, T., see Kato, N. 50, 77

- Takahashi, K., see Kunitomi, M. 50, 109
- Tanabe, T., see Kawasaki, T. 50, 97
- Telci, A., U. Çakatay, S. Salman, İ. Satman, A. Sivas, Oxidative protein damage in early stage Type 1 diabetic patients 50, 213
- Toyoda, N., see Sugaya, A. 50, 57
- Turner, R.C., see MacNamara, C.M. 50, 117
- Van Acker, K., M. Oleen-Burkey, L. De Decker, R. Vanmaele, P. Van Schil, G. Matricali, H. Dys, I. De Leeuw, Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium 50, 87
- Vanmaele, R., see Van Acker, K. 50, 87
- Van Schil, P., see Van Acker, K. 50, 87
- Vu, H., see Davis, T.M.E. 50, 153
- Wada, J., see Kunitomi, M. 50, 109
- Wall, S., see Jonsson, P.M. 50, 35
- Watala, C., see Sobol, A.B. 50, 1
- Wikblad, K.F., see Sandberg, G.E. 50, 27
- Wong, G.W.K., P.S. Cheng, T.F. Leung, Sex differences in the growth of diabetic children 50, 187
- Yagihashi, S., see Kato, N. 50, 77
- Yamanouchi, T., see Kawasaki, T. 50, 97
- Yoshimura, T., see Kawasaki, T. 50, 97



Subject index of volume 50

- Absorption;** Insulin; Concentration; NPH; Semilente **50**, 161
- Acarbose;** Metformin; Type 2 diabetes; Glycaemic control **50**, 49
- Albuminuria;** Sialic acid; Type 2 diabetes; Kuwaiti subjects **50**, 65
- Amylin;** Islet amyloid polypeptide; Proinsulin; Impaired fasting glucose; C-peptide; Type 2 diabetes **50**, 117
- Angiotensin-converting enzyme;** Gene polymorphism; Diabetes mellitus; Proliferative retinopathy; Nephropathy **50**, 195
- 1,5-Anhydroglucitol;** Polygalae radix; Traditional Chinese medicines; Type 2 diabetes mellitus **50**, 97
- Antihypertensive medication;** Oral glucose tolerance test; Prognostic factor; Hypertension; Population-based study **50**, 231
- Aspirin;** Diabetes mellitus; Platelets; Platelet hyperreactivity; Cardiovascular disease **50**, 1
- Autoimmune diabetes;** IA-2; PTP35; Neuroendocrine tissues **50**, 17
- Carbonyl groups;** Type 1 diabetes; Protein oxidation; Nitrotyrosine; Lipid peroxidation **50**, 213
- Cardiovascular disease;** Cystatin C; Creatinine; Homocysteine; Diabetic nephropathy; Type 2 diabetes mellitus **50**, 177
- Cardiovascular disease;** Diabetes mellitus; Platelets; Platelet hyperreactivity; Aspirin **50**, 1
- Cardiovascular disease;** Prevalence; Type 2 diabetes **50**, 137
- cGMP;** Endothelin-1; Type 2 diabetes; IGT; Neopterin **50**, 127
- Children;** Growth; Diabetic; Chinese **50**, 187
- Chinese;** Growth; Diabetic; Children **50**, 187
- Cognitive impairment;** Diabetes; Elderly; Dementia; Self-care; Screening **50**, 203
- Complications of mother and infant;** Gestational diabetes mellitus; Diagnostic criteria **50**, 57
- Concentration;** Absorption; Insulin; NPH; Semilente **50**, 161
- Correlation;** FPG; 2-h PG; HbA1c **50**, 225
- Cost of illness;** Foot ulcer; Diabetes mellitus; Economic analysis **50**, 87
- Costs and cost analysis;** Diabetes care; Health services/utilization; Sweden **50**, 35
- C-peptide;** Islet amyloid polypeptide; Amylin; Proinsulin; Impaired fasting glucose; Type 2 diabetes **50**, 117
- Creatinine;** Cardiovascular disease; Cystatin C; Homocysteine; Diabetic nephropathy; Type 2 diabetes mellitus **50**, 177
- Cystatin C;** Cardiovascular disease; Creatinine; Homocysteine; Diabetic nephropathy; Type 2 diabetes mellitus **50**, 177
- Dementia;** Diabetes; Elderly; Cognitive impairment; Self-care; Screening **50**, 203
- Dental caries;** Type 2 diabetes; Oral health; Periodontal disease; Xerostomia **50**, 27
- Diabetes care;** Costs and cost analysis; Health services/utilization; Sweden **50**, 35
- Diabetes;** Elderly; Cognitive impairment; Dementia; Self-care; Screening **50**, 203

- Diabetes mellitus;** Angiotensin-converting enzyme; Gene polymorphism; Proliferative retinopathy; Nephropathy 50, 195
- Diabetes mellitus;** Foot ulcer; Cost of illness; Economic analysis 50, 87
- Diabetes mellitus;** Platelets; Platelet hyperreactivity; Cardiovascular disease; Aspirin 50, 1
- Diabetic;** Growth; Children; Chinese 50, 187
- Diabetic nephropathy;** Cardiovascular disease; Cystatin C; Creatinine; Homocysteine; Type 2 diabetes mellitus 50, 177
- Diabetic rats;** Long-term aldose reductase inhibition; Peripheral neuropathy; Fidaostat 50, 77
- Diagnostic criteria;** Gestational diabetes mellitus; Complications of mother and infant 50, 57
- Economic analysis;** Foot ulcer; Diabetes mellitus; Cost of illness 50, 87
- Elderly;** Diabetes; Cognitive impairment; Dementia; Self-care; Screening 50, 203
- Endothelin-1;** cGMP; Type 2 diabetes; IGT; Neopterin 50, 127
- Fidaostat;** Long-term aldose reductase inhibition; Diabetic rats; Peripheral neuropathy 50, 77
- Foot ulcer;** Diabetes mellitus; Cost of illness; Economic analysis 50, 87
- Forced expiratory volume in 1 s;** Type 2 diabetes mellitus; Forced vital capacity; Vital capacity; Peak expiratory flow rate 50, 153
- Forced vital capacity;** Type 2 diabetes mellitus; Forced expiratory volume in 1 s; Vital capacity; Peak expiratory flow rate 50, 153
- FPG;** Correlation; 2-h PG; HbA1c 50, 225
- GADA;** IA-2A; Type 1 diabetes 50, 147
- Gene polymorphism;** Angiotensin-converting enzyme; Diabetes mellitus; Proliferative retinopathy; Nephropathy 50, 195
- Gestational diabetes mellitus;** Diagnostic criteria; Complications of mother and infant 50, 57
- Glucokinase;** Post-renal transplantation diabetes mellitus; Mutations 50, 169
- Glycaemic control;** Acarbose; Metformin; Type 2 diabetes 50, 49
- Glycaemic control;** Type 1 diabetes; Smoking; Locus of control beliefs 50, 103
- Growth;** Diabetic; Children; Chinese 50, 187
- HbA1c;** Correlation; FPG; 2-h PG 50, 225
- Health services/utilization;** Diabetes care; Costs and cost analysis; Sweden 50, 35
- Homocysteine;** Cardiovascular disease; Cystatin C; Creatinine; Diabetic nephropathy; Type 2 diabetes mellitus 50, 177
- 2-h PG;** Correlation; FPG; HbA1c 50, 225
- HR_{max};** Ventilatory threshold; HR_{reserve}; Rating of perceived exertion 50, 109
- HR_{reserve};** Ventilatory threshold; HR_{max}; Rating of perceived exertion 50, 109
- Hypertension;** Oral glucose tolerance test; Prognostic factor; Antihypertensive medication; Population-based study 50, 231
- IA-2A;** GADA; Type 1 diabetes 50, 147
- IA-2;** PTP35; Autoimmune diabetes; Neuroendocrine tissues 50, 17
- IGT;** Endothelin-1; cGMP; Type 2 diabetes; Neopterin 50, 127
- Impaired fasting glucose;** Islet amyloid polypeptide; Amylin; Proinsulin; C-peptide; Type 2 diabetes 50, 117
- Insulin;** Absorption; Concentration; NPH; Semilente 50, 161
- Islet amyloid polypeptide;** Amylin; Proinsulin; Impaired fasting glucose; C-peptide; Type 2 diabetes 50, 117
- Kuwaiti subjects;** Sialic acid; Type 2 diabetes; Albuminuria 50, 65
- Lipid peroxidation;** Type 1 diabetes; Protein oxidation; Carbonyl groups; Nitrotyrosine 50, 213
- Locus of control beliefs;** Type 1 diabetes; Glycaemic control; Smoking 50, 103
- Long-term aldose reductase inhibition;** Diabetic rats; Peripheral neuropathy; Fidaostat 50, 77
- Metformin;** Acarbose; Type 2 diabetes; Glycaemic control 50, 49
- Mutations;** Post-renal transplantation diabetes mellitus; Glucokinase 50, 169

- Neopterin**; Endothelin-1; cGMP; Type 2 diabetes; IGT 50, 127
- Nephropathy**; Angiotensin-converting enzyme; Gene polymorphism; Diabetes mellitus; Proliferative retinopathy 50, 195
- Neuroendocrine tissues**; IA-2; PTP35; Autoimmune diabetes 50, 17
- Nitrotyrosine**; Type 1 diabetes; Protein oxidation; Carbonyl groups; Lipid peroxidation 50, 213
- NPH**; Absorption; Insulin; Concentration; Semilente 50, 161
- Oral glucose tolerance test**; Prognostic factor; Antihypertensive medication; Hypertension; Population-based study 50, 231
- Oral health**; Type 2 diabetes; Periodontal disease; Dental caries; Xerostomia 50, 27
- Peak expiratory flow rate**; Type 2 diabetes mellitus; Forced vital capacity; Forced expiratory volume in 1 s; Vital capacity 50, 153
- Periodontal disease**; Type 2 diabetes; Oral health; Dental caries; Xerostomia 50, 27
- Peripheral neuropathy**; Long-term aldose reductase inhibition; Diabetic rats; Fidarestat 50, 77
- Platelet hyperreactivity**; Diabetes mellitus; Platelets; Cardiovascular disease; Aspirin 50, 1
- Platelets**; Diabetes mellitus; Platelet hyperreactivity; Cardiovascular disease; Aspirin 50, 1
- Polygalae radix**; 1,5-Anhydroglucitol; Traditional Chinese medicines; Type 2 diabetes mellitus 50, 97
- Population-based study**; Oral glucose tolerance test; Prognostic factor; Antihypertensive medication; Hypertension 50, 231
- Post-renal transplantation diabetes mellitus**; Glucokinase; Mutations 50, 169
- Prevalence**; Type 2 diabetes; Cardiovascular disease 50, 137
- Prognostic factor**; Oral glucose tolerance test; Antihypertensive medication; Hypertension; Population-based study 50, 231
- Proinsulin**; Islet amyloid polypeptide; Amylin; Impaired fasting glucose; C-peptide; Type 2 diabetes 50, 117
- Proliferative retinopathy**; Angiotensin-converting enzyme; Gene polymorphism; Diabetes mellitus; Nephropathy 50, 195
- Protein oxidation**; Type 1 diabetes; Carbonyl groups; Nitrotyrosine; Lipid peroxidation 50, 213
- PTP35**; IA-2; Autoimmune diabetes; Neuroendocrine tissues 50, 17
- Rating of perceived exertion**; Ventilatory threshold; HR_{max} ; $HR_{reserve}$ 50, 109
- Screening**; Diabetes; Elderly; Cognitive impairment; Dementia; Self-care 50, 203
- Self-care**; Diabetes; Elderly; Cognitive impairment; Dementia; Screening 50, 203
- Semilente**; Absorption; Insulin; Concentration; NPH 50, 161
- Sialic acid**; Type 2 diabetes; Kuwaiti subjects; Albuminuria 50, 65
- Smoking**; Type 1 diabetes; Glycaemic control; Locus of control beliefs 50, 103
- Sweden**; Diabetes care; Costs and cost analysis; Health services/utilization 50, 35
- Traditional Chinese medicines**; 1,5-Anhydroglucitol; Polygalae radix; Type 2 diabetes mellitus 50, 97
- Type 2 diabetes**; Acarbose; Metformin; Glycaemic control 50, 49
- Type 2 diabetes**; Endothelin-1; cGMP; IGT; Neopterin 50, 127
- Type 1 diabetes**; Glycaemic control; Smoking; Locus of control beliefs 50, 103
- Type 1 diabetes**; IA-2A; GADA 50, 147
- Type 2 diabetes**; Islet amyloid polypeptide; Amylin; Proinsulin; Impaired fasting glucose; C-peptide 50, 117
- Type 2 diabetes mellitus**; 1,5-Anhydroglucitol; Polygalae radix; Traditional Chinese medicines 50, 97
- Type 2 diabetes mellitus**; Cardiovascular disease; Cystatin C; Creatinine; Homocysteine; Diabetic nephropathy 50, 177
- Type 2 diabetes mellitus**; Forced vital capacity; Forced expiratory volume in 1 s; Vital capacity; Peak expiratory flow rate 50, 153
- Type 2 diabetes**; Oral health; Periodontal disease; Dental caries; Xerostomia 50, 27

Type 2 diabetes; Prevalence; Cardiovascular disease **50**, 137

Type 1 diabetes; Protein oxidation; Carbonyl groups; Nitrotyrosine; Lipid peroxidation **50**, 213

Type 2 diabetes; Sialic acid; Kuwaiti subjects; Albuminuria **50**, 65

Ventilatory threshold; HR_{max}; HR_{reserve}; Rating of perceived exertion **50**, 109

Vital capacity; Type 2 diabetes mellitus; Forced vital capacity; Forced expiratory volume in 1 s; Peak expiratory flow rate **50**, 153

Xerostomia; Type 2 diabetes; Oral health; Periodontal disease; Dental caries **50**, 27

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100